NuCana Presents Data On NUC-3373 In Colorectal Cancer At The AACR-NCI-EORTC International Conference On Molecular Targets And Cancer Therapeutics 2023
Portfolio Pulse from Benzinga Newsdesk
NuCana plc (NASDAQ:NCNA) presented data from two ongoing clinical studies with NUC-3373 in colorectal cancer at the AACR-NCI-EORTC International Conference. The data showed promising anti-tumor activity and a favorable safety profile. The NuTide:302 study showed that patients receiving NUC-3373-based regimens achieved a longer progression-free survival compared to their first-line treatment with 5-FU-based therapy. The ongoing Phase 2 NuTide:323 study is recruiting well with no new safety signals.
October 13, 2023 | 4:32 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
NuCana's NUC-3373 shows promising results in ongoing clinical studies for colorectal cancer. The data presented indicates a favorable safety profile and anti-tumor activity, potentially boosting investor confidence in the company.
The positive data from the ongoing clinical studies of NUC-3373 in colorectal cancer is likely to boost investor confidence in NuCana. The favorable safety profile and anti-tumor activity of the drug could potentially lead to its approval and subsequent commercial success, positively impacting the company's stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100